About OraPharma
OraPharma is a company based in Bridgewater (United States) founded in 1997 was acquired by Bausch Health in June 2012. OraPharma has raised $16 million across 1 funding round from investors including Bausch Health, Frazier Healthcare Partners and Canaan. OraPharma offers products and services including Arestin and OSSIX Portfolio. OraPharma operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Bridgewater, United States
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website orapharma.com
- Social LinkedIn
- Acquired by Bausch Health (Jun 2012)
- Legal Name Orapharma Inc
- Total Equity Funding$16M (USD)
in 1 rounds
- Latest Funding Round$16M (USD), Series C
Dec 1998
- InvestorsBausch Health
& 7 more
- Acquired by
Products & Services of OraPharma
OraPharma offers a comprehensive portfolio of products and services, including Arestin and OSSIX Portfolio.
Antibacterial microspheres for managing gum disease in patients.
Regenerative materials for bone and tissue grafting procedures.
Funding Insights of OraPharma
OraPharma has successfully raised a total of $16M through 1 strategic funding round. The most recent funding activity was a Series C round of $16 million completed in December 1998. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16M
- Total Rounds 1
- Last Round Series C — $16M
- First Round $16M
(Dec 1998)
- Investors Count 6
All 1 funding rounds of OraPharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 1998 | $16M | Series C | – | – |
8 investors in total: 8 institutional.
Investors in OraPharma
OraPharma has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Bausch Health, Frazier Healthcare Partners and Canaan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Early-stage companies are invested in globally by TL Ventures. | – | tl.ventures | Wayne, United States | |
Life science & tech focused VC firm investing in the US | – | domainvc.com | Princeton, United States | |
- | – | healthcap.eu | - | |
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Venture capital investments are made in disruptive growth companies. | – | oakvc.com | Greenwich, United States | |
Water Street is engaged in strategic investments in healthcare sectors. | 2005 | waterstreet.com | Chicago, United States | |
Therapeutics for multiple diseases including dermatology and neurology are developed. | 1960 | bauschhealth.com | Laval, Canada |
Investor details for OraPharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OraPharma
789 people are tracked at OraPharma (353 in leadership, 11 in board & advisors, 425 in team).
| Name | Role | Group |
|---|---|---|
Travis Covington | Vp, Strategic Robotics R&d | Leadership |
Richard Tillyer | Global Head, Discovery, Product Development & Supply, Janssen Research and Development | Leadership |
Thomas O'Gara | Senior Director, Strategic Demand & Capacity Management | Leadership |
Hitesh Vora | Director | Leadership |
Deepak Bandyopadhyay | Director, Data Science, R&d Quality | Leadership |
Sue Hohenleitner | VP, Finance, Johnson & Johnson Innovation | Leadership |
Charles Nau | Director | Leadership |
Anand Narayanan | Director | Leadership |
Neema Kulkarni | Associate Director, Global Topical Healthcare | Leadership |
Alice Pizzelanti | Head Of Hr, Janssen US Commercial Centers Of Excellence | Leadership |
Anuj Terapanthi | IT Director - Platform Leader, Finance Data & Analytics | Leadership |
Chandra Branham | Senior Director, Payment & Care Delivery, Health Policy | Leadership |
Minh Miran | Global Sr. Director, Strategy & Operations | Leadership |
Hoang Lu (Jack) | Director | Leadership |
Bert Bruyninckx | Director | Leadership |
Juan Velez | IT Director | Leadership |
Liz Rivett | Director | Leadership |
Carol Boyne | Director | Leadership |
Wael Adhami | Vice President, Global Trade Controls | Leadership |
Andrea Kollath | Director | Leadership |
769 more people are available in the full profile.
Complete people profiles for OraPharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of OraPharma
5 dated milestones of OraPharma across 15 years, from founding to its latest funding, stage changes and deals.
- Founded OraPharma is founded.
- Funding First funding round of $16.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Water Street.
- Exit Acquired by Bausch Health.
Competitors of OraPharma
OraPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of OraPharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OraPharma
The website of OraPharma (orapharma.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 94.3% vs previous month
Websites whose visitors overlap most with OraPharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
quigleyco.com | quigleyco.com | 100% | – | – | – |
| qltinc.com | 100% | 2.4K | #6,312,210 | View details | |
andromaco.com.ar | andromaco.com.ar | 100% | – | #5,663,664 | – |
| ventanamed.com | 100% | – | – | View details | |
| salix.com | 100% | 15.6K | #1,433,848 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 28 similar websites and full traffic analytics for OraPharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 28 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Orapharma
Complete news archive for OraPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to OraPharma
10 companies that operate in the same segment as OraPharma (Dental Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Custom 3D printed dental aligners are developed for teeth straightening. | 2017 | New York, New York, United States | USD 147.78 M | – | – | |
Invisalign clear aligners and dental products are developed. | 1997 | Tempe, Arizona, United States | USD 101 M | – | 1,051 | |
Provider of 3D ear scanning systems | 2000 | Copenhagen, Denmark | USD 36.01 K | – | 1 | |
Dental implants and regenerative dentistry products are developed. | 1954 | Basel, Basel-stadt, Switzerland | – | USD 3.29 B | – | |
Optical equipment for micron-level surface geometry capture is offered. | 2011 | Waltham, Massachusetts, United States | USD 16.22 M | – | – | |
Dental implant solutions are provided for patients and professionals. | 2000 | Harrogate, United Kingdom | USD 30.01 M | – | – | |
Dental implants and biomaterials are developed by Keystone Dental. | 2006 | Burlington, Vermont, United States | USD 86.24 M | – | – | |
Therapy devices and software for treating tooth decay are developed. | 2006 | Laguna Hills, California, United States | USD 285.41 M | USD 28.55 M | 131 | |
Invisible braces and oral care products are developed and provided. | 2018 | Singapore, Singapore | USD 55.1 M | – | – | |
Implants for dental and spine treatments are developed. | 2022 | Westminster, United States | – | USD 449.75 M | 1,770 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OraPharma
OraPharma was founded in 1997 and raised its 1st funding round 1 year after it was founded.
OraPharma is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
OraPharma is a funded company, having raised a total of $16M across 1 funding round to date. The company's 1st funding round was a Series C of $16M, raised on Dec 1998.
OraPharma is developing products that help improve and maintain oral health. ARESTIN (minocycline HCl) Microspheres, 1 mg is a locally administered antibiotic (LAA) offering a patented microsphere technology for the treatment of periodontitis as an adjunct to scaling and root planing. Another product ONSET, a delivery system of locally buffered anesthesia that can provide faster onset of anesthesia and more comfortable injection. Other products include EZ white for whitening, ossix plus for tissue regeneration, and neutrasal for dryness of oral mucosa.
OraPharma's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
OraPharma offers Arestin and OSSIX Portfolio.
OraPharma has 8 investors. Key investors include Bausch Health, Frazier Healthcare Partners, Canaan, TL Ventures, and Domain Associates.
OraPharma operates through Orapharma Inc.
Yes. OraPharma was acquired by Bausch Health in June 2012.